Bernardo Imbroda-Herrera
Malaga, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 03, 2025
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Journal: Future oncology (London, England)
Published: November 11, 2025
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels.
Journal: Current opinion in urology
Published: October 09, 2025
Emerging Molecular and Computational Biomarkers in Urothelial Carcinoma: Innovations in Diagnosis, Prognosis, and Therapeutic Response Prediction.
Journal: Journal of personalized medicine
Published: October 01, 2025
BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 14, 2025
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial.
Journal: The Lancet. Oncology
Published: February 05, 2025
The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder Cancer.
Journal: Diagnostics (Basel, Switzerland)
Published: October 11, 2024
Bulbar urethroplasty techniques and stricture recurrence: differences between end-to-end urethroplasty versus the use of graft.
Journal: Minerva urology and nephrology
Published: July 24, 2024
Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results.
Journal: Cancer medicine
Published: June 24, 2024
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial.
Journal: European urology
Published: December 20, 2023
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532).
Journal: European urology oncology
Published: October 30, 2023
Last Updated: 09/26/2026